Vor Biopharma Inc.
Performance History
| Key Stats | |
|---|---|
| Open | $1.81 |
| Prev. Close | $1.81 |
| EPS | -1.89 |
| Dividend | $0.00 |
| Next Earnings Date | Aug 10, 2023 |
| Dividend Yield % | - |
| Market Cap | $122.05M |
| PE Ratio | - |
| low | high | |
|---|---|---|
| Day Range | 1.76 | 1.90 |
| 52 Week Range | 1.62 | 7.57 |
| Ratios | |
|---|---|
| P/B Ratio | 0.70 |
| Revenue | - |
| Operating M. % | 0.00% |
| Earnings | -$115.51M |
| Earnings Growth % | - |
| EBITDA Margin % | - |
| ROE % | -69.27% |
| EPS | -1.89 |
Score Breakdown
All Score (42 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
| VOR | Market | |
|---|---|---|
| Value | 64 | 42 |
| Quality | 39 | 46 |
| Ownership | 24 | 39 |
| Growth | 24 | 44 |
| Dividends | - | 32 |
All Score (42 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
Financial Forecast
AI Price Prediction
Analyst Ratings
Correlated Companies
About Vor Biopharma Inc. (VOR)
Vor Biopharma Inc., a clinical-stage company, engages in the development of engineered hematopoietic stem cell (eHSC) therapies for cancer patients. The company is developing lead product, tremtelectogene empogeditemcel (trem-cel), formerly VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. It also offers Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, currently under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system, currently under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system, made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, currently under preclinical studies for the treatment of AML. Vor Biopharma Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
- ISN
- -
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Robert Ang M.B.A., M.D., MBBS
- Headquarters
- Cambridge
- Employees
- 133
Keep an eye on Vor Biopharma Inc.
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
News
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.